載入中
Replimune Group, Inc. is a biotechnology enterprise dedicated to pioneering oncolytic immuno-gene therapies aimed at treating various cancers. The company leverages its proprietary Immunotherapy platform to engineer and advance novel therapeutic candidates designed to activate the body's immune system against malignant cells. Its leading experimental drug, RP1, is a selectively replicating variant of the herpes simplex virus 1. This candidate is presently in Phase I/II clinical trials for a range of solid tumors and has also progressed to Phase II trials specifically for patients with cutaneous squamous cell carcinoma. Replimune is additionally developing RP2, an anti-CTLA-4 antibody-like protein, which is undergoing Phase I clinical assessment. Its purpose is to counteract the immune system's suppression often mediated by CTLA-4. Furthermore, RP3, also in Phase I clinical trials, is engineered to express immune-activating proteins that stimulate T cells. Established in 2015, Replimune Group, Inc. maintains its corporate headquarters in Woburn, Massachusetts.
前收盤價
US$13.20
−US$0.05 · -0.38%
盤前
US$13.20
US$0.00 · 0.00%
10月8日 上午4:11 ET
盤中時間採用ET。市場資料可能有所延遲。
Replimune Group, Inc. is a biotechnology enterprise dedicated to pioneering oncolytic immuno-gene therapies aimed at treating various cancers. The company leverages its proprietary Immunotherapy platform to engineer and advance novel therapeutic candidates designed to activate the body's immune system against malignant cells. Its leading experimental drug, RP1, is a selectively replicating variant of the herpes simplex virus 1. This candidate is presently in Phase I/II clinical trials for a range of solid tumors and has also progressed to Phase II trials specifically for patients with cutaneous squamous cell carcinoma. Replimune is additionally developing RP2, an anti-CTLA-4 antibody-like protein, which is undergoing Phase I clinical assessment. Its purpose is to counteract the immune system's suppression often mediated by CTLA-4. Furthermore, RP3, also in Phase I clinical trials, is engineered to express immune-activating proteins that stimulate T cells. Established in 2015, Replimune Group, Inc. maintains its corporate headquarters in Woburn, Massachusetts.
日內區間
目前US$13.20
52週區間
目前US$13.20
盤中時間採用ET。市場資料可能有所延遲。
Replimune Group, Inc. is a biotechnology enterprise dedicated to pioneering oncolytic immuno-gene therapies aimed at treating various cancers. The company leverages its proprietary Immunotherapy platform to engineer and advance novel therapeutic candidates designed to activate the body's immune system against malignant cells. Its leading experimental drug, RP1, is a selectively replicating variant of the herpes simplex virus 1. This candidate is presently in Phase I/II clinical trials for a range of solid tumors and has also progressed to Phase II trials specifically for patients with cutaneous squamous cell carcinoma. Replimune is additionally developing RP2, an anti-CTLA-4 antibody-like protein, which is undergoing Phase I clinical assessment. Its purpose is to counteract the immune system's suppression often mediated by CTLA-4. Furthermore, RP3, also in Phase I clinical trials, is engineered to express immune-activating proteins that stimulate T cells. Established in 2015, Replimune Group, Inc. maintains its corporate headquarters in Woburn, Massachusetts.
日內區間
目前US$13.20
52週區間
目前US$13.20
已公布業績及可用的市場共識預估。
已公布業績及可用的市場共識預估。
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$18.67
上漲空間 41.44%報告持有此股票曝險的交易所交易基金。
State Street SPDR S&P Biotech ETFXBI3453萬0.33%100.75億 USD0.35%US$150.23-0.44%
Vanguard Morningstar Total Stock Market ETFVTI3018.21萬0.00%2.3兆 USD0.03%US$381.03-0.40%
iShares Russell 2000 ETFIWM2783.49萬0.04%785.63億 USD0.19%US$277.7-1.29%
Vanguard Extended Market ETFVXF1332.72萬0.01%954億 USD0.05%US$233.49-1.56%
iShares Biotechnology ETFIBB876.68萬0.08%104.01億 USD0.44%US$203.34+0.12%
Vanguard Russell 2000 ETFVTWO695.99萬0.04%180億 USD0.06%US$112.21-1.26%
Schwab U.S. Small-Cap ETFSCHA553.61萬0.03%220.14億 USD0.03%US$32.61-1.47%
F/M Emerald Life Sciences Innovation ETFLFSC538.7萬4.64%1.16億 USD0.79%US$41.8366-0.65%State Street SPDR S&P Biotech ETFXBIVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAF/M Emerald Life Sciences Innovation ETFLFSCAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
